Nov 7, 2025 · Learn about ORSERDU®, the only NCCN Clinical Practice Guidelines in Oncology–recommended treatment option for ESR1-mutated, HR+/HER2- mBC.

The EMERALD trial led to the approval of elacestrant for estrogen receptor (ER)–positive, HER2-negative, estrogen receptor 1 (ESR1)–mutated advanced or metastatic breast cancer (mBC) with …

May 28, 2025 · 1070Background: Progression of ER+/HER2- mBC on 1L endocrine therapy (ET) + CDK4/6i is associated with several mechanisms of resistance that impact efficacy and subsequent …

Evaluate ORSERDU®, a treatment option for ESR1-mutated, ER+/HER2-advanced or metastatic breast cancer following disease progression on endocrine therapy.

Aug 20, 2024 · Early results from the ELEVATE trial (NCT05563220), a phase 1b/2 study of elacestrant (Orserdu) given in combination with various targeted therapies, showed promise when used for the …

Sep 3, 2024 · For patients with hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) metastatic breast cancer (mBC) progressed on first-line endocrine …

Jun 19, 2025 · This analysis evaluates the benefit of elacestrant in patients with high vs low ESR1 VAF. Materials and Methods Patients with ER+/HER2– mBC and 1 to 2 lines prior ET, mandatory …

Apr 3, 2025 · Key Takeaways Oral SERDs like elacestrant offer convenience but show modest efficacy as monotherapy for ESR1-mutated HR+/HER2– MBC.

Oct 11, 2023 · The approval of elacestrant as a subsequent line of therapy for patients with ER+/HER2- metastatic breast cancer offers a novel therapeutic option in a setting that previously had limited …

In the UK, Korserdu® (elacestrant) monotherapy is indicated for the treatment of postmenopausal women, and men, with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 …